TARS Stock: Price, Earnings History and SEC Filings
Tarsus Pharmaceuticals, Inc. (TARS) last traded at $74.85, up 0.88% on the latest session and down 4.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.43 against an analyst estimate of $-0.21, a miss of 104.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TARS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.43 | $-0.21 | -104.76% |
| Mar 2026 | May 6, 2026 | $-0.16 | $-0.46 | +65.22% |
| Dec 2025 | Feb 23, 2026 | $-0.20 | $-0.19 | -5.26% |
| Sep 2025 | Nov 4, 2025 | $-0.30 | $-0.35 | +14.29% |
TARS beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How TARS reacts to earnings
Across its last 8 earnings releases, TARS moved 6.4% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +6.59% |
| 2026-05-06 | After close | -1.24% |
| 2026-02-23 | After close | +7.79% |
| 2025-11-04 | After close | -4.62% |
| 2025-08-06 | After close | +15.15% |
| 2025-05-01 | After close | -5.84% |
| 2025-02-25 | Before open | -9.33% |
| 2024-11-13 | After close | +0.31% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TARS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $451M | -$66M | -$22M | -14.7% | $-1.59 |
| 2024 | $183M | -$116M | -$85M | -63.2% | $-3.07 |
| 2023 | $17M | -$136M | -$119M | -778.9% | $-4.62 |
| 2022 | $26M | -$62M | -$50M | -240.5% | $-2.52 |
| 2021 | $57M | -$14M | $3M | -24.2% | $-0.67 |
| 2020 | $0 | -$27M | -$22M | – | $-4.32 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TARS
- 8-K · Sep 10, 2026Acquisition or disposal completed, Other events, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Aug 6, 2026Material agreement, Unregistered share sale, Other events
- 8-K · Aug 6, 2026Material agreement, Unregistered share sale, Other events
- 8-K · Jul 13, 2026Officer or director change
- 8-K · Jul 8, 2026Material agreement, Unregistered share sale, Other events
- 8-K · Jun 29, 2026Shareholder vote
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
Insider filing activity
TARS insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TARS news
- Gilead Sciences (GILD) Q3 Earnings and Revenues Top EstimatesOct 29, 2026 · finance.yahoo.com
- Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026Oct 29, 2026 · finance.yahoo.com
- Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings GrowthOct 28, 2026 · finance.yahoo.com
- Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial OfficerOct 28, 2026 · finance.yahoo.com
- Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineOct 27, 2026 · finance.yahoo.com
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (TARS) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.